



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC Handels GmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic)




Product Information

Description:	This anti-APRIL neutralizing antibody is a purified, humanized recombinant monoclonal antibody that recognizes human APRIL (A proliferation-inducing ligand). This antibody has been tested for activity in a binding assay. It is similar to Sibeprenlimab.
Background:	APRIL (A proliferation-inducing ligand), also known as TNSF13 or CD256, activates a signaling pathway that participates in the regulation of B-cell development, autoimmunity, and long-term plasma cell survival. This protein is a member of the tumor necrosis factor (TNF) ligand family and a ligand for BCMA/ TNFRSF17. APRIL expression is significantly elevated in multiple myeloma (MM), and it has been demonstrated that activation of BCMA by APRIL promotes tumor growth, chemoresistance, and immunosuppression in the bone marrow microenvironment. Anti-APRIL monoclonal antibodies, such as sibeprenlimab and zigakibart, have recently progressed to clinical trials for Immunoglobulin A Nephropathy (IgAN) and MM, respectively. The development of a modified TACI (transmembrane activator and CAML interactor) domain resulted in Povetacicept, or ALPN-303, a dual inhibitor of APRIL and BAFF, with potential applications in the treatment of autoimmune disorders.
Species:	Human
Isotype:	IgG2
Clonality:	Monoclonal
Concentration:	1.91 mg/ml
Expression System:	HEK293
Purity:	≥90%
Format:	Aqueous buffer solution.
Formulated In:	8 mM phosphate, pH 7.4, 110 mM NaCl, 2.2 mM KCl, and 20% glycerol
MW:	Heavy chain: 49 kDa + glycans; Light chain: 24 kDa
Endotoxin Level:	2.7 EU/mg
Glycosylation:	This antibody runs at a higher MW by SDS-PAGE due to glycosylation.
Stability:	At least 6 months at -80°C.
Storage:	-80°C
Instructions for Use:	Thaw on ice and gently mix prior to use. DO NOT VORTEX. Perform a quick spin before opening. Aliquot into small volumes and flash freeze for long term storage. Avoid multiple freeze/thaw cycles.
Assay Conditions:	A white 96-well plate was precoated with APRIL, His-Avi-Tag Recombinant (#100254) (100 ng/well). Blocking Buffer 2 (#79728) and PBST were used for blocking and washing steps, respectively. For protein titration a serial dilution of Anti-APRIL Neutralizing Antibody (#102736) at the highest concentration of 10 ng/μl (250 ng/reaction) was prepared in 1x PP-02 Assay Buffer (#82620). Diluted Anti-APRIL Neutralizing Antibody was then added to the wells and plate was incubated at Room Temperature (RT) for 1 hour. The plate was then washed again and incubated with anti-Fc-HRP conjugate diluted 1:1000 in Blocking Buffer 2 for 1 hour at RT. After the final wash, ELISA ECL mix (#79670) was added to each well and chemiluminescence was read.
Applications:	Useful for binding assays.

Quality Control Data

4-20% SDS-PAGE Coomassie Staining



APRIL:anti-APRIL Binding Activity

